Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Results of a randomized trial presented at the American Psychiatric Association conference show the GeneSight Psychotropic genetic test can improve the treatment of depression by identifying the medications most and least likely to be effective.
Latest From Clinical Trials
Results of a study showed that Impulse Dynamics' Optimizer device significantly improved exercise tolerance and quality of life in certain heart-failure patients. See what principal investigator (and cardiologist) William Abraham of Ohio State University said about those patients here.
The FIX-HF-5C trial, a subgroup study derived from the FIX-HF-5 pivotal trial, shows that the Impulse Dynamics Optimizer cardiac contractility modulation device significantly improved exercise tolerance and quality of life in certain heart-failure patients. Results of the trial were presented at the Heart Rhythm Society conference in Boston. Impulse Dynamics expects to file the final PMA module for US FDA for Optimizer in June.
iSTAR Medical reported six-month clinical trial data supporting its latest micro-invasive glaucoma surgery device, MINIject.
Starts & Stops compiles all the clinical trial announcements, initiations, completions and suspensions tracked by Meddevicetracker. This edition covers trial announcements made between May 7 and 13, 2018, including announcements from BioCardia, Akili Interactive Labs, Arch Therapeutics, and Acutus Medical.
The long-awaited results of the CABANA trial, a large randomized study comparing ablation to drug therapy as a first-line treatment for atrial fibrillation, were presented at the Heart Rhythm Society conference in Boston on May 10. The trial missed its primary endpoint in the "intent to treat" analysis, but showed a significant benefit for ablation in the "as-treated" analysis.
On this week’s podcast, Marion Webb reports on emerging exoskeleton technology to help patients recovering from spinal cord injuries or stroke, and Catherine Longworth reports on BioTrinity 2018 in London, a gathering of investors and medtech innovators.
A new "standard charging methodology" is to be introduced across NHS England to allow drug and device clinical trials to get underway faster. Presently, there can be a difference of up to nine months between confirmations being issued by each NHS hospital taking part in a multi-site trial.
Starts & Stops compiles all the clinical trial announcements, initiations, completions and suspensions tracked by Meddevicetracker. This edition covers trial announcements made between April 30-May 7, 2018, including announcements from Biosense Webster, Endonovo Therapeutics, Intact Vascular, and NeoChord.
See what Global Kinetics Corporation CEO John Schellhorn told Medtech Insight about what the firm's wearable Parkinson's disease monitor brings to clinicians and patients after gaining multi-source funding for a randomized trial.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.